Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine

医学 奥马佐单抗 内型 精密医学 疾病 临床试验 个性化医疗 免疫学 单克隆抗体 靶向治疗 美波利祖马布 血管性水肿 杜皮鲁玛 塞库金单抗 重症监护医学 生物标志物 单克隆抗体治疗 生物信息学 分子诊断学 单克隆 临床实习 免疫疗法
作者
Klara Andrzejczak,Wiktor Witkowski,Joanna Górka-Dynysiewicz,Robert Pawłowicz,Agnieszka Kopeć
出处
期刊:Pharmaceutics [Multidisciplinary Digital Publishing Institute]
卷期号:18 (9): 1169-1169
标识
DOI:10.3390/pharmaceutics18091169
摘要

Chronic spontaneous urticaria (CSU) is a common and heterogeneous inflammatory skin disease characterized by recurrent wheals and/or angioedema for more than six weeks. Despite treatment with second-generation antihistamines, many patients remain symptomatic, highlighting the need for therapies targeting underlying pathogenic mechanisms. AIM: This review summarizes current knowledge on CSU immunopathogenesis and targeted therapies, with a focus on personalized medicine. METHODS: A literature review was conducted, focusing on recent advances in CSU endotypes and clinical trial data on biologic, small-molecule, and other targeted therapies acting on key immunological pathways. RESULTS: CSU is increasingly recognized as a heterogeneous disease with distinct immunological endotypes, including type I (autoallergic) and type IIb (autoimmune), which may influence treatment response. Omalizumab remains the mainstay of second-line therapy, although many patients do not achieve complete disease control. Emerging therapies, including anti-IL-4Rα monoclonal antibodies (dupilumab), Bruton's tyrosine kinase inhibitors (e.g., remibrutinib), and anti-c-KIT monoclonal antibodies (e.g., barzolvolimab, briquilimab), have demonstrated promising efficacy. Some show a rapid onset of action, although preferential efficacy in specific CSU endotypes remains to be established. Several clinical and laboratory features, including total IgE, anti-TPO antibodies, ASST, basophil reactivity, basopenia, eosinopenia, and atopic comorbidities, have been investigated as potential markers of endotype and treatment response; however, their utility for treatment selection remains insufficiently validated. CONCLUSIONS: Advances in understanding CSU pathogenesis have enabled the development of targeted therapies that may improve disease control. Predictive biomarkers and endotypic characterization may support the future development of more personalized therapeutic strategies; however, clinically validated biomarkers for treatment selection remain limited, and prospective validation of biomarker-guided approaches is still needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哭泣觅儿完成签到,获得积分10
刚刚
ubless607举报云郁闷的求助涉嫌违规
刚刚
芝麻发布了新的文献求助10
刚刚
白白白完成签到,获得积分10
1秒前
含糊的绝山完成签到,获得积分10
1秒前
顺利的含玉完成签到,获得积分10
1秒前
超级的友儿完成签到,获得积分10
1秒前
vcc完成签到,获得积分10
1秒前
1秒前
刘雪完成签到 ,获得积分10
2秒前
Tex完成签到,获得积分10
2秒前
2秒前
灭法者完成签到,获得积分10
2秒前
2秒前
碧蓝铁身发布了新的文献求助10
3秒前
3秒前
可儿demi完成签到,获得积分10
3秒前
小蘑菇的应助被reck采纳,获得10
3秒前
Clarence发布了新的文献求助10
3秒前
joy完成签到,获得积分10
4秒前
大方的契完成签到,获得积分10
4秒前
4秒前
4秒前
科研小能手的应助被Jeff采纳,获得80
4秒前
Maestro_S的应助被碧蓝的若风采纳,获得10
4秒前
美好小丸子完成签到,获得积分10
4秒前
xiaohan完成签到,获得积分10
4秒前
RAL发布了新的文献求助10
4秒前
海绵宝宝电棍完成签到,获得积分10
4秒前
5秒前
jiang完成签到 ,获得积分10
5秒前
搜集达人的应助被TaoTaooooII采纳,获得10
5秒前
yy完成签到,获得积分10
5秒前
Rg完成签到,获得积分10
5秒前
聂的苏完成签到 ,获得积分10
5秒前
5秒前
英吉利25发布了新的文献求助10
6秒前
6秒前
泡沫完成签到,获得积分10
6秒前
爱悠悠完成签到 ,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174136
求助须知:如何正确求助?哪些是违规求助? 9566193
关于积分的说明 21785238
捐赠科研通 7768317
什么是DOI,文献DOI怎么找? 3431698
关于科研通互助平台的介绍 2555912
邀请新用户注册赠送积分活动 2476956